Expanded Access Policy

Xeris recognizes that patients may seek access to medicines currently in our pipeline through Expanded Access. Our Expanded Access Policy is outlined here.

Expanded Access Policy

Xeris is committed to developing medicines that address unmet medical needs. This is accomplished through the:

  • Conduct of clinical trials
  • Subsequent regulatory approval
  • Commercialization of our products

More information about clinical trials with Xeris investigational products can be found at clinicaltrials.gov.

Xeris also recognizes that patients with serious or life-threatening diseases may have exhausted all available treatment options and may not be able to participate in a clinical trial. These patients may seek access to investigational medicines, a process called Expanded Access, Compassionate Use, Early Access, Special Access, or by another name based on the country from which the request is being made. If you are a Healthcare Professional that would like to make a request for Expanded Access of a Xeris investigational product, please email eap@xerispharma.com. Within this initial request, please include the following information:

  • Name and Contact number of physician
  • Specific compound that is being requested
  • Do not include any information that may identify the patient

If you are a patient and would like to make a request for Expanded Access of a Xeris investigational product, please work directly with your healthcare professional.

BACK
TO TOP